THER-09. ONCOLYTIC ADENOVIRUS, DNX-2401, FOR NAIVE DIFFUSE INTRINSIC PONTINE GLIOMAS: A PHASE I CLINICAL TRIAL
Ignacio Íñigo-Marco(Navarre Institute of Health Research), Marta M. Alonso(BioCruces Health research Institute), Guillermo Aldave(Baylor College of Medicine), Blanca López‐Ibor, Sandra Hervás, Jaime Gállego Pérez de Larraya(Clinica Universidad de Navarra), Carlos DeAndrea(Clinica Universidad de Navarra), Chris Jones(North Carolina State University), Sonia Tejada(Universidad de Navarra), María Buñales, Marc García-Moure(Navarre Institute of Health Research), Juàn Fueyo(The University of Texas MD Anderson Cancer Center), Rubén Hernández, Ricardo Díez-Valle(Navarre Institute of Health Research), Marisol González-Huarriz(Navarre Institute of Health Research), María Villalba(Navarre Institute of Health Research), Candelaria Gomez‐Manzano(The University of Texas MD Anderson Cancer Center), Esther Hulleman(Amsterdam UMC Location VUmc), Alan Mackay(Institute of Cancer Research), Ana Patiño‐García(Navarre Institute of Health Research), Jasper van der Lugt(Princess Máxima Center), Ibón Tamayo
Cited by 1
Related Papers
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
|Cancer Cell|2017|1.3k
BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells
|Cell stem cell|2010|814
<i>FGFR1</i> Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
|Cancer Research|2010|740
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711